Table 2.
List prices per vial for originator and biosimilar etanercept, authors’ estimates of rebated prices, and costs for county councils and the Government after gainsharing in the third managed entry agreement on subcutaneous tumour necrosis factor-α inhibitors (1 October 2017 to 30 September 2019) [19, 20]
| Product | List price per vial (SEK)a | Estimated rebate (SEK)a | Estimated rebated price (SEK) | Estimated savings (SEK) | Estimated cost (SEK) | ||
|---|---|---|---|---|---|---|---|
| CCb | Governmentc | CC | Government | ||||
| Current situation (as of 1 March 2018) | |||||||
| Enbrel® (50 mg, 4 vials) | 1899 | 1540 (65% of price at start of agreement) | 359 | 924 | 616 | 975 | 1283 |
| Benepali® (50 mg, 4 vials) | 1514 | 0 (0%) | 1514 | 0 | 0 | 1514 | 1514 |
| Erelzi® (50 mg, 4 vials) | 1144 | 0 (0%) | 1144 | 0 | 0 | 1144 | 1144 |
| Benepali® (50 mg, 12 vials) | 774 | 0 (0%) | 755 | 0 | 0 | 774 | 774 |
| At time of third managed entry agreement (1 October 2017) | |||||||
| Enbrel® (50 mg, 4 vials) | 2370 | 1540 (65%) | 830 | 924 | 616 | 1446 | 1754 |
| Benepali® (50 mg, 4 vials) | 1514 | 0 (0%) | 1514 | 0 | 0 | 1514 | 1514 |
| Erelzi® (50 mg, 4 vials) | 1514 | 0 (0%) | 1514 | 0 | 0 | 1514 | 1514 |
CC county council, SEK Swedish kronor
aA rebate level of 65% was applied to the list price of the originator product, but no additional rebates/discounts were taken into account for Benepali® and Erelzi®, although this might not reflect reality
b60% of savings (rebate) for the CC in gainsharing agreement with the Government
c40% of savings (rebate) for the Government in gainsharing agreement with the CCs